Abstract
Deflazacort is a prednisolone-derived immunosuppressant and anti-inflammatory. It controls cytokines and immune cell development. It may increase muscle cell proliferation and reduce muscle breakdown to enhance Duchenne muscular dystrophy muscle strength and function. Pharmaceutical companies aim to produce high-quality drugs at low prices. Pharmaceutical formulation discovery, development, and evaluation require validated methods. Validation ensures quality and reliability throughout the manufacturing process. The validation procedure evaluates accuracy, specificity, precision, and system applicability to guarantee the analytical technique used to analyze medicine-related samples is reliable. This paper describes the deflazacort technique development and validation. Google Scholar, Pub-Med, and Shodganga are utilized to gather information.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
